Juan Manuel Igea
Juan Manuel Igea has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Alonso‐Gómez
Hospital Felipe II Recoletas Valladolid Spain
1 shared publication - Alvaro Moreno-Ancillo
Allergy Section Hospital General Universitario Nuestra Señora del Prado Talavera de la Reina Toledo Spain
1 shared publication - Antonio Letrán
Allergy Unit Hospital HLA Jerez Puerta del Sur Jerez de la Frontera Cádiz Spain
1 shared publication Beatriz Pola Bibián
Centro Médico Zaragoza Zaragoza Spain
1 shared publication- Berta Ruiz‐León
Immunology and Allergy Clinical Management Unit (UGC), Hospital Universitario Reina Sofía (HURS) Maimónides Biomedical Research Institute of Córdoba (IMIBIC)/HURS/University of Córdoba Córdoba Spain
1 shared publication - Carmelo Escudero
Allergy Department Hospital Infantil Universitario Niño Jesús Madrid Spain
1 shared publication
Latest Publications
- 19 November 2026
- Published by Wiley in Clinical & Experimental Allergy
NavigAIT.me, a Digital Intervention to Improve Long‐Term Adherence in Allergen Immunotherapy: Design of a Multicentre Randomised Trial
Summary: Evaluating the real‐life effectiveness of a new digital intervention to improve persistence in allergen immunotherapy (AIT). Assessing persistence, implementation, effectiveness and satisfaction with AIT in a randomised controlled prospective large‐scale trial.
- 19 November 2026
- Published by Wiley in Clinical & Experimental Allergy
NavigAIT.me, a Digital Intervention to Improve Long‐Term Adherence in Allergen Immunotherapy: Design of a Multicentre Randomised Trial
Summary: Evaluating the real‐life effectiveness of a new digital intervention to improve persistence in allergen immunotherapy (AIT). Assessing persistence, implementation, effectiveness and satisfaction with AIT in a randomised controlled prospective large‐scale trial.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 19, 1-11
A Multi-Compartment Cytological Approach to Severe Asthma Phenotyping: The BRISA Study (Biomedical Research in Severe Asthma)
Background: Accurate inflammatory phenotyping in asthma remains challenging. Nasal cytology has emerged as a potential non-invasive tool to assess airway inflammation in asthma. However, its relationship with lower airway inflammation and systemic biomarkers remains unclear, particularly in severe asthma (SA). Objective: To evaluate whether a multi-compartment approach could improve the characterisation of type 2 inflammation and the relationship between nasal cytology, induced sputum, and systemic inflammatory biomarkers in patients with severe asthma. Methods: In this cross-sectional exploratory BRISA study, twenty-two patients with SA underwent nasal cytology by mucosal scraping, induced sputum analysis, and serum biomarker assessment (periostin, eosinophil cationic protein, thymic stromal lymphopoietin, dipeptidyl peptidase-4, and total IgE). Patients were stratified according to blood eosinophil count (BEC < 300 vs ≥ 300 cells/μL). Correlations between compartments and associations with clinical and inflammatory variables were analysed. Results: Higher blood eosinophil counts were associated with worse lung function, increased exacerbations, and higher serum periostin levels. Valid induced sputum samples were obtained in 16 patients: 7 eosinophilic, 3 neutrophilic, 2 mixed eosinophilic-neutrophilic and 4 paucigranulocytic. Nasal cytology predominantly showed limited agreement with induced sputum inflammatory phenotypes. Serum TSLP, DPP4, and IgE also showed an upward trend in patients with higher blood eosinophil counts, although these differences were not statistically significant. Correlation analysis demonstrated a significant positive association between sputum and blood eosinophils, as well as between blood eosinophils and serum periostin. A strong positive correlation was also observed between serum eotaxin and TSLP. Conclusion: Nasal cytology alone cannot replace induced sputum for inflammatory phenotyping in SA, although it may provide complementary information on upper airway inflammation. Among the evaluated systemic biomarkers, periostin emerged as the most consistent marker associated with blood eosinophilia, while other biomarkers showed only non-significant trends. Further studies are needed to validate the role of combined biomarkers in predicting airway inflammation.
- 1 May 2026
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 19, 1-11
Open AccessA Multi-Compartment Cytological Approach to Severe Asthma Phenotyping: The BRISA Study (Biomedical Research in Severe Asthma)
Background: Accurate inflammatory phenotyping in asthma remains challenging. Nasal cytology has emerged as a potential non-invasive tool to assess airway inflammation in asthma. However, its relationship with lower airway inflammation and systemic biomarkers remains unclear, particularly in severe asthma (SA). Objective: To evaluate whether a multi-compartment approach could improve the characterisation of type 2 inflammation and the relationship between nasal cytology, induced sputum, and systemic inflammatory biomarkers in patients with severe asthma. Methods: In this cross-sectional exploratory BRISA study, twenty-two patients with SA underwent nasal cytology by mucosal scraping, induced sputum analysis, and serum biomarker assessment (periostin, eosinophil cationic protein, thymic stromal lymphopoietin, dipeptidyl peptidase-4, and total IgE). Patients were stratified according to blood eosinophil count (BEC < 300 vs ≥ 300 cells/μL). Correlations between compartments and associations with clinical and inflammatory variables were analysed. Results: Higher blood eosinophil counts were associated with worse lung function, increased exacerbations, and higher serum periostin levels. Valid induced sputum samples were obtained in 16 patients: 7 eosinophilic, 3 neutrophilic, 2 mixed eosinophilic-neutrophilic and 4 paucigranulocytic. Nasal cytology predominantly showed limited agreement with induced sputum inflammatory phenotypes. Serum TSLP, DPP4, and IgE also showed an upward trend in patients with higher blood eosinophil counts, although these differences were not statistically significant. Correlation analysis demonstrated a significant positive association between sputum and blood eosinophils, as well as between blood eosinophils and serum periostin. A strong positive correlation was also observed between serum eotaxin and TSLP. Conclusion: Nasal cytology alone cannot replace induced sputum for inflammatory phenotyping in SA, although it may provide complementary information on upper airway inflammation. Among the evaluated systemic biomarkers, periostin emerged as the most consistent marker associated with blood eosinophilia, while other biomarkers showed only non-significant trends. Further studies are needed to validate the role of combined biomarkers in predicting airway inflammation.